

PRODUCT MONOGRAPH

PrLEUCOVORIN CALCIUM INJECTION USP

10 mg/mL

Sterile Solution

THERAPEUTIC CLASSIFICATION

Folic Acid Derivative

Pfizer Canada ULC
17300 Trans-Canada Highway
Kirkland, Québec
H9J 2M5

Date of Revision:
L3: 03 June 2020 (June 21, 2018)

Submission Control Number: (215416)

^{Pr}Leucovorin Calcium Injection USP

10 mg/mL

Sterile Solution

THERAPEUTIC CLASSIFICATION

Folic acid derivative

Since leucovorin may enhance the toxicity of fluorouracil, combination therapy consisting of leucovorin and fluorouracil for advanced colorectal cancer should be administered under the supervision of a physician experienced in the use of antimetabolite cancer chemotherapy. Particular care should be taken in the treatment of elderly or debilitated colorectal cancer patients, as these patients may be at increased risk of severe toxicity. Death from severe enterocolitis, diarrhea and dehydration has been reported in elderly patients receiving leucovorin and fluorouracil. Concomitant granulocytopenia and fever were present in some but not all of the patients.

INDICATIONS AND CLINICAL USE

Leucovorin Calcium Injection USP is indicated:

- To diminish the toxicity and counteract the effects of overdosage of folic acid antagonists.
- To diminish the systemic toxicity of methotrexate after administration of methotrexate as a chemotherapeutic agent, as part of chemotherapeutic treatment programs in the management of several forms of cancer.
- To treat megaloblastic anemias due to folate deficiency, as in sprue and other nutritional deficiencies; and megaloblastic anemias of pregnancy and infancy (see **CONTRAINDICATIONS**).
- For pre-treatment followed by fluorouracil to prolong survival in the palliative treatment of patients with advanced colorectal cancer.

CONTRAINDICATIONS

Leucovorin Calcium Injection USP is contraindicated for:

- Pernicious anemia therapy or other megaloblastic anemias secondary to a deficiency of vitamin B₁₂. Its use can lead to an apparent response of the hematopoietic system, but neurological damage may occur or progress if already present.
- Known hypersensitivity to this drug or to any ingredient in the formulation or component of the container.
- Intrathecal administration.

SERIOUS WARNINGS AND PRECAUTIONS

- **Leucovorin Calcium Injection USP should only be given by intramuscular or intravenous injection and must not be administered intrathecally (see CONTRAINDICATIONS and DOSAGE AND ADMINISTRATION). Death has been reported when folinic acid has been administered intrathecally following intrathecal overdose of methotrexate.**
- **Leucovorin Calcium Injection USP should only be used with 5-fluorouracil or methotrexate under the direct supervision of a clinician experienced in the use of cancer chemotherapeutic agents.**
- **Patients receiving any combination therapy regimen involving leucovorin and fluorouracil should be carefully monitored for diarrhea and/or stomatitis/mucositis as these are the first indications that severe and potentially life-threatening toxicity could develop (see WARNINGS and DRUG INTERACTIONS).**
- **Fatalities have occurred as a result of gastrointestinal toxicity (predominantly mucositis and diarrhoea) (see WARNINGS and ADVERSE REACTIONS).**
- **Fatalities have occurred as a result of myelosuppression (see WARNINGS and ADVERSE REACTIONS).**
- **Cases of Stevens-Johnson Syndrome (SJS) and Toxic Epidermal Necrolysis (TEN), some fatal, have been reported in patients receiving leucovorin in combination therapy (see ADVERSE REACTIONS).**
- **Leucovorin may diminish the effect of anti-epileptic substances such as phenobarbital, primidone and phenytoin. During leucovorin administration in epileptic patients treated with these substances, there is a risk to increase the frequency of seizures due to a decrease of plasma concentrations of anti-epileptic**

drugs (see DRUG INTERACTIONS).

WARNINGS

In cases of overdosage of folic acid antagonists, prompt administration of leucovorin calcium is essential; if a period of more than four hours intervenes, the treatment may be ineffective due to the time delay. Monitoring of the serum methotrexate concentration is essential in determining the optimal dose of leucovorin to give and duration of therapy. Delayed methotrexate excretion may be an indication of a third space fluid accumulation (i.e. ascites, pleural effusion), renal insufficiency, low pH of urine or inadequate hydration. Higher doses of leucovorin or prolonged administration may be indicated in such cases. Leucovorin has no apparent effect on pre-existing methotrexate nephrotoxicity.

Excessive leucovorin doses must be avoided since this might impair the antitumour activity of methotrexate, especially in CNS tumours where leucovorin accumulates after repeated courses.

Resistance to methotrexate as a result of decreased membrane transport implies also resistance to folinic acid rescue as both medicinal products share the same transport system.

In case of co-administration of leucovorin and fluorouracil, diarrhea and/or stomatitis/mucositis are the first indications that severe and potentially life-threatening toxicity could develop. Patients who experience these symptoms while receiving any combination therapy regimen involving leucovorin and fluorouracil should be carefully monitored. Generally these symptoms are controllable by reducing the dose of fluorouracil. Treatment-related deaths have been sporadically reported in patients receiving leucovorin/fluorouracil combination therapy.

Leucovorin enhances the toxicity of fluorouracil. When these drugs are administered concurrently in the palliative therapy of advanced colorectal cancer, the dosage of fluorouracil must be reduced. Although the toxicities observed in patients treated with the combination of leucovorin and fluorouracil are qualitatively similar to those observed in patients treated with fluorouracil alone, gastrointestinal toxicities (particularly stomatitis and diarrhea) are observed more commonly and may be more severe in patients receiving the combination therapy.

Therapy with leucovorin/fluorouracil must not be initiated or continued in patients who have symptoms of gastrointestinal toxicity of any severity, until those symptoms have resolved. Patients with diarrhea must be closely monitored until the diarrhea has resolved, as rapid clinical deterioration leading to death can occur. Elderly or debilitated patients are at greater risk for severe toxicity when receiving this therapy. In elderly patients, it is recommended to begin with a reduced dosage of fluorouracil.

PRECAUTIONS

General

Leucovorin should be used with caution after methotrexate chemotherapy, when the following medical problems exist:

- Aciduria (urine pH less than 7)
- Ascites
- Dehydration (**Note:** Inadequate hydration including that secondary to vomiting may also result in increased methotrexate toxicity.)
- Gastrointestinal obstruction
- Pleural or peritoneal effusions
- Renal function impairment (**Note:** Risk of methotrexate toxicity is increased because elimination of methotrexate may be impaired and accumulation may occur; even small doses of methotrexate may lead to severe myelosuppression and mucositis; larger doses and/or increased duration of leucovorin treatment may be necessary.)

Patient monitoring is recommended when leucovorin is administered as part of methotrexate chemotherapy programs. Monitoring may include creatinine clearance determinations prior to therapy; plasma or serum methotrexate determinations to detect developing renal function impairment (an increase of greater than 50% within 24 hours is associated with severe renal toxicity); urine pH determination (recommended every 6 hours to ensure that the pH remains greater than 7.0 to minimize the risk of methotrexate nephropathy). Leucovorin has no apparent effect on pre-existing methotrexate nephrotoxicity.

Calcium levels should be monitored in patients receiving combined leucovorin /5-fluorouracil treatment and calcium supplementation should be provided if calcium levels are low. Complete blood count (CBC) with differential and platelets: prior to each treatment; weekly during the first two courses; at time of anticipated white blood cell (WBC) nadir in all courses thereafter. Electrolytes and liver function tests: prior to each treatment for the first three courses and prior to every other course thereafter.

Pregnancy, Reproduction, Lactation

Problems have not been documented. It is not known whether leucovorin is excreted in breast milk.

Leucovorin is an intermediate product in the metabolism of folic acid and occurs naturally in the body. Hence, nonclinical reproductive toxicity studies were not conducted.

There are no adequate and well-controlled clinical studies conducted in pregnant or breast-feeding

women. No formal animal reproductive toxicity studies with calcium folinate have been conducted.

Calcium folinate in combination with 5-fluorouracil is not recommended for use in woman who are breast-feeding.

Age-Related Effects

No information is available regarding the use of leucovorin in geriatrics. Leucovorin may increase the frequency of seizures in susceptible children.

Elderly patients are at greater risk of developing severe toxicity when treated with the combination of leucovorin plus fluorouracil for the palliative treatment of colorectal cancer.

DRUG INTERACTIONS

Serious Drug-Drug Interactions

- **Patients receiving any combination therapy regimen involving leucovorin and fluorouracil should be carefully monitored for diarrhea and/or stomatitis/mucositis as these are the first indications that severe and potentially life-threatening toxicity could develop (see WARNINGS and DRUG INTERACTIONS).**
- **Leucovorin may diminish the effect of anti-epileptic substances such as phenobarbital, primidone and phenytoin. During leucovorin administration in epileptic patients treated with these substances, there is a risk to increase the frequency of seizures due to a decrease of plasma concentrations of anti-epileptic drugs (see DRUG INTERACTIONS).**
- **Leucovorin enhances the cytotoxicity and toxicity of fluorouracil. Leucovorin must not be mixed with fluorouracil in the same intravenous injection or infusion (see DRUG INTERACTIONS).**

The following drugs or combinations containing these drugs may interact with leucovorin with clinical significance:

- Anticonvulsants, barbiturate
- Anticonvulsant, hydantoin
- Primidone

Large doses of leucovorin may counteract the anticonvulsant effects of these medications.

Leucovorin may diminish the effect of anti-epileptic substances such as phenobarbital, primidone and phenytoin. During leucovorin administration in epileptic patients treated with these substances, there is a risk to increase the frequency of seizures (a diminution of plasma levels of enzymatic inductor anticonvulsant drugs may be observed because the hepatic metabolism is increased, as folates are one of the cofactors). Clinical monitoring, possibly monitoring of the plasma concentrations and, if necessary, dose adaptation of the anti-epileptic drug during leucovorin administration and after discontinuation is recommended.

- Folic acid antagonist
When leucovorin is given in conjunction with a folic acid antagonist (e.g., cotrimoxazole, pyrimethamine, methotrexate, antibiotic with antifolic effect), the efficacy of the folic acid antagonist may either be reduced or completely neutralized.
- Di-aminopyrimidines (there is some evidence that concomitant administration of leucovorin and trimethoprim (or co-trimoxazole) may inhibit the antibiotic effect of trimethoprim)

Leucovorin administered concomitantly with methotrexate may nullify the antitumour chemotherapeutic effect of the latter drug (see **DOSAGE AND ADMINISTRATION**).

Leucovorin has been administered simultaneously with pyrimethamine without interfering with its anti-malarial therapy.

Leucovorin enhances the cytotoxicity and toxicity of fluorouracil. Leucovorin must not be mixed with fluorouracil in the same intravenous injection or infusion.

ADVERSE REACTIONS

Table 1: Adverse Drug Reactions during Leucovorin Calcium Monotherapy

System Organ Class	ADR Term
General disorders and administrations site conditions	Pyrexia
Immune system disorders	Hypersensitivity
	Anaphylactic reaction
	Anaphylactic shock
Nervous system disorders	Seizure
	Syncope
Skin and subcutaneous tissue disorders	Urticaria
	Stevens-Johnson Syndrome
	Toxic Epidermal Necrolysis

Cases of Stevens-Johnson Syndrome (SJS) and Toxic Epidermal Necrolysis (TEN), some fatal, have been reported in patients receiving leucovorin in combination with other agents known to be associated with these disorders. A contributory role of leucovorin in these occurrences of SJS/TEN cannot be excluded.

Allergic reactions, wheezing, skin rash, hives or itching occur rarely. In combination regimens, the toxicity of fluorouracil is enhanced by leucovorin. The most common manifestations are mucositis, stomatitis, leukopenia and/or diarrhea which may be dose-limiting. In clinical trials with this drug combination, these toxicities were found to be controllable by appropriately reducing the dose of fluorouracil.

Generally, the safety profile depends on the applied regimen of 5-fluorouracil due to enhancement of the 5-fluorouracil induced toxicities. Additional undesirable effects, when used in combination with 5-fluorouracil, are presented in **Table 2**.

Table 2: Adverse Drug Reactions during Leucovorin Calcium Combination Therapy with 5-fluorouracil

System Organ Class	Adverse Drug Reaction
Blood and lymphatic system disorders	Leukopenia, Neutropenia, Thrombocytopenia, Anemia
Gastrointestinal disorders	Nausea, Vomiting, Diarrhea, Stomatitis
General disorders and administration site conditions	Mucosal inflammation
Metabolism and nutrition disorders	Hyperammonemia
Skin and subcutaneous tissue disorders	Palmar-plantar Erythrodysesthesia syndrome (hand-foot syndrome)

Fatalities have occurred as a result of gastrointestinal toxicity (predominantly mucositis and diarrhea) and myelosuppression. In patients with diarrhea, rapid clinical deterioration leading to death can occur.

Reporting Suspected Side Effects

You can report any suspected side effects associated with the use of health products to Health Canada by:

- Visiting the Web page on Adverse Reaction Reporting (<https://www.canada.ca/en/health-canada/services/drugs-health-products/medeffect-canada/adverse-reaction-reporting.html>) for information on how to report online, by mail or by fax; or
- Calling toll-free at 1-866-234-2345.

NOTE: Contact your health professional if you need information about how to manage your side effects. The Canada Vigilance Program does not provide medical advice.

SYMPTOMS AND TREATMENT OF OVERDOSAGE

Leucovorin has very low acute and subchronic toxicity in animals. There has been no experience with overdosage of parenteral leucovorin in humans.

For management of a suspected drug overdose, contact your regional Poison Control Centre immediately.

DOSAGE AND ADMINISTRATION

Leucovorin Calcium Injection USP may be administered as received by intramuscular injection or intravenous injection, or it may be diluted for intravenous infusion (see **PHARMACEUTICAL INFORMATION: Dilution for Intravenous Infusion**).

Due to calcium content of leucovorin solution, no more than 160 mg of leucovorin should be injected, per minute, intravenously.

Treatment of Overdosage of Folic Acid Antagonists:

In cases of overdosage of folic acid antagonists, prompt administration of leucovorin calcium is essential; if a period of more than four hours intervenes, the treatment may be ineffective.

The dose of leucovorin calcium should be equal to or greater than the suspected dose of folic acid antagonist.

Where large doses of methotrexate have been given, leucovorin may be administered by intravenous infusion in doses up to 75 mg within 12 hours, followed by 12 mg intramuscularly every six hours, for four doses. In less severe overdosage, 6 to 12 mg of leucovorin may be given intramuscularly every six hours, for four doses, until the serum methotrexate level is less than 10^{-8} M.

Use After Chemotherapy with Methotrexate:

The dosage and scheduling of doses of leucovorin varies, but it is normally given about 6 to 24 hours following methotrexate administration, in amounts equal to the weight of methotrexate given. Serum creatinine and methotrexate levels should be determined at 24-hour intervals. If the 24-hour serum creatinine has increased 50% over baseline or if the 24-hour methotrexate level is greater than 5×10^{-6} M or the 48-hour level is greater than 9×10^{-7} M, the dose of leucovorin should be increased to 100 mg/m² intravenously every 3 hours until the methotrexate level is less than 10^{-8} M.

Hydration (3 L/day) and urinary alkalization with NaHCO₃ should be employed concomitantly. The bicarbonate dose should be adjusted to maintain the urine pH at 7.0 or greater.

In most cases, leucovorin should not be administered simultaneously with systemic methotrexate, since the therapeutic effect of the antimetabolite may be nullified. However, when methotrexate is administered by intra-arterial (regional perfusion) or intrathecal injection, leucovorin may be given (intramuscularly, intravenously or orally) concomitantly, to offset systemic methotrexate toxicity without abolishing the local activity of the cytotoxic drug.

Treatment of Megaloblastic Anemia:

For treatment of megaloblastic anemia due to folate deficiency, the dose should not exceed 1 mg daily. The duration of therapy depends on the hematologic response to the drug. Oral leucovorin is preferred to parenteral therapy, except where cases of severe vomiting impair drug absorption when administered orally.

Treatment of Advanced Colorectal Cancer:

Leucovorin is administered at 200 mg/m² by slow intravenous injection prior to dosing with 370 mg/m² fluorouracil by slow intravenous injection, for 5 consecutive days.

This 5-day treatment course may be repeated at 4-week (28 days) intervals, provided that the patient has completely recovered from the toxic effects of the prior treatment course.

In subsequent treatment courses, the dosage of fluorouracil should be adjusted based on patient tolerance of the prior treatment course. The daily dosage of fluorouracil should be reduced by 20% for patients who experienced moderate hematologic or gastrointestinal toxicity in the prior treatment course, and by 30% for patients who experienced severe toxicity. For patients who did not experience toxicity in the prior treatment course, fluorouracil dosage may be increased by 10%. Leucovorin dosages are not adjusted for toxicity.


PHARMACEUTICAL INFORMATION

Drug Substance

Common Name(s): Leucovorin calcium. Also known as calcium folinate, citrovorum factor and folinic acid.

Chemical Name: L-glutamic acid, N-(4-((2-amino-5-formyl-1, 4, 5, 6, 7, 8-hexahydro-4-oxo-6-pteridiny)methyl)amino)benzoyl)-calcium salt (1:1).

Chemical Structure:



Molecular Formula: $C_{20}H_{21}CaN_7O_7 \cdot 5H_2O$

Molecular Weight: 601.62

Description: Leucovorin is a mixture of the diastereoisomers of 5-formyltetrahydrofolic acid, the biologically active component of the mixture being the (-)-L-isomer.

Leucovorin calcium occurs as a yellowish to beige, odourless powder, which is very soluble in water and practically insoluble in alcohol. The hydrated salt contains 8 to 15% water. The optical rotation (concentration = 2.5% in water) is $+14.5^\circ$ to $+16.5^\circ$ for the anhydrous substance. The pH is 7.5 to 8.5 for this 2.5% aqueous solution.

Composition: Leucovorin Calcium Injection USP is a sterile solution of leucovorin (as the calcium salt), supplied as 10 mg/mL, in water for injection with sodium chloride 8.5 mg/mL, added for isotonicity. **Contains no preservatives.** Sodium hydroxide or hydrochloric acid may be used for pH adjustment.

Stability and Storage Recommendations: Leucovorin Calcium Injection USP should be stored refrigerated (2°C to 8°C), and protected from light and freezing.

Dilution for Intravenous Infusion: When required for intravenous infusion, Leucovorin Calcium Injection USP may be diluted with 5% Dextrose Injection, 0.9% Sodium Chloride Injection, Lactated Ringer's Injection or Ringer's Injection to give a final concentration of 0.05 mg/mL leucovorin. These dilutions may be stored for 24 hours at room temperature. Due to the possibility of antimicrobial contamination, unused solution should be discarded after that time.

Dilutions with the hypertonic infusion solutions, 10% Dextrose Injection and 5% Dextrose in 0.9% Sodium Chloride Injection, may also be prepared to a final concentration of 0.05 mg/mL of leucovorin. However, these dilutions should be stored for no longer than 8 hours at room temperatures. Unused solution should be discarded after that time.

Dispensing of Pharmacy Bulk Vials: Leucovorin Calcium Injection USP, 10 mg/mL, is supplied as 500 mg in 50 mL of sterile, unpreserved, isotonic solution (see **Composition** above).

The use of Pharmacy Bulk Vials is restricted to hospitals with a recognized intravenous admixture program. The Pharmacy Bulk vial is intended for single puncture, multiple dispensing, and for intravenous use only.

Contents of the Pharmacy Bulk vials should be dispensed within eight hours of the initial entry because of the potential for microbial contamination. Discard any unused portion. The diluted solutions prepared from the Pharmacy Bulk Vial should be used within 24 hours if kept at room temperature, from the time of the initial entry into the Pharmacy Bulk vial. However, the product diluted with hypertonic infusion solutions is restricted to 8 hours if kept at room temperature, from the time of the initial entry into the Pharmacy Bulk Vial.

Pharmacy Bulk Vials contain no preservatives. Care must be taken to minimize the potential for inadvertent introduction of microorganisms during manipulation in the hospital environment.

Warning: As with all parenteral drug products, intravenous admixtures should be inspected visually for clarity, particulate matter, precipitate, discoloration and leakage prior to administration, whenever solution and container permit. Solutions showing haziness, particulate matter, precipitate, discoloration or leakage should not be used.

AVAILABILITY OF DOSAGE FORMS

Leucovorin Calcium Injection USP is available as a 10 mg/mL sterile, unpreserved, isotonic solution of leucovorin (as the calcium salt), in 5 mL (50 mg/5 mL) single-use vials.

Leucovorin Calcium Injection USP is available as a 10 mg/mL sterile, unpreserved, isotonic solution of leucovorin (as the calcium salt), in a 50 mL (500 mg/50 mL) Pharmacy Bulk Vial for intravenous administration only. The Pharmacy Bulk Vial is supplied to hospitals with a recognized intravenous admixture program only.

ACTION AND CLINICAL PHARMACOLOGY

Leucovorin is a reduced form of folic acid, which is readily converted to other reduced folic acid derivatives (e.g., tetrahydrofolate). Because it does not require reduction by dihydrofolate reductase as does folic acid, leucovorin is not affected by blockages of this enzyme by folic acid antagonists (dihydrofolate reductase inhibitors). This allows purine and thymidine synthesis, and thus DNA, RNA and protein synthesis to occur. Leucovorin may limit methotrexate action on normal cells by competing with methotrexate for the same transport processes into the cell.

Leucovorin enhances the cytotoxicity of fluoropyrimidines such as fluorouracil by their metabolites, methylene tetrahydrofolate and fluorodeoxyuridine monophosphate, forming a stable ternary complex with thymidylate synthase and thereby decreasing intracellular levels of that enzyme and the product thymidylate. The cell then dies as a result of thymine starvation.

A folic acid deficiency is produced during therapy with the folic acid antagonists aminopterin and amethopterin (methotrexate) used as antineoplastic agents and with the chemotherapeutic agent pyrimethamine. These agents competitively inhibit the conversion of folic acid to folinic acid. Their affinity for folate reductase is so much greater than that of folic acid that not even large doses of folic acid will correct the drug-induced deficiency. In the event of a severe toxic reaction, the already reduced form, folinic acid, can be given, since it can be used directly to form new coenzyme.

Thirty minutes following oral administration of leucovorin calcium, 92 to 93% of total reduced folates in serum were assayable as 5-methyltetrahydrofolate. The determination of 5-methyltetrahydrofolate was carried out by the use of a differential microbiological disc assay procedure utilizing methotrexate resistant strains of *Lactobacillus casei* and *Streptococcus faecium* var. *durans*. Peak serum levels of 5-methyltetrahydrofolate were reached earlier following intramuscular administration (approximately 45 minutes) than after oral administration (approximately 2 hours).

Similar results were obtained after oral administration of radiolabelled leucovorin calcium. These studies also indicated substantial metabolism of leucovorin calcium during transfer from gastrointestinal tract to the systemic circulation, since 90% of the serum folate was identified as 5-methyltetrahydrofolate by chromatographic techniques.

The serum half-life of leucovorin (or 5-formyltetrahydrofolate) was 35 to 45 minutes following both oral and intramuscular administration. The serum half-life of 5-methyltetrahydrofolate was about 2 1/4 hours. 5-methyltetrahydrofolate was excreted via the kidneys in a manner proportional to its serum concentration.

Methotrexate did not seem to affect the absorption of folate.

TOXICITY

In mice, the LD₅₀ was 991 mg/kg intravenously. Toxic symptoms included body tremors, marked ataxia, clonic convulsions and deaths within 10 minutes in CD-1 male mice. The single-dose oral LD₅₀ could not be determined because, at doses as high as 20,000 mg/kg, no toxicity was observed in CD-1 and Long-Evans male rats. Doses higher than this could not be given because of the limitations of dose volume and viscosity.

In subchronic studies, oral doses of leucovorin at 0, 75, 225 or 675 mg/kg daily for over 30 days to rats and beagle dogs produced no drug-related toxic effects on body weight, food consumption, hematology, blood chemistry, urinalysis or pathology. No alteration in ECG in dogs occurred. Ophthalmoscopic examinations of rats and dogs revealed no drug-induced toxic effects.

BIBLIOGRAPHY

1. Advani PP, Fakih MG. **5-FU-induced hyperammonemic encephalopathy in a case of metastatic rectal adenocarcinoid successfully rechallenged with the fluoropyrimidine analog, capecitabine.** *Anticancer Res* 2011;31(1):335-8.
2. Benchalal M, Yahchouchy-Chouillard E, Fouere S, Fingerhut A. **Anaphylactic shock secondary to intravenous administration of folinic acid: a first report.** *Ann Oncol.* 2002 Mar;13(3):480-1.
3. Bender, J.F., Grove, W.R. and Fortner, C.L. **High-dose methotrexate with folinic acid rescue.** 1977. *Am. J. Hosp. Pharm.* 34:961.
4. Bertrand M., Doroshov J.H., Multhauf P., Blayney D.W., Carr B.I., Cecchi G., Goldberg D., Leong L., Margolin K., Metter G., Staples R. **High-dose continuous infusion folinic acid and bolus 5-Fluorouracil in patients with advanced colorectal cancer: A phase II study.** *J Clin Oncol* 1986; 4:1058-61.
5. Bleyer WA. **New vistas for leucovorin in cancer chemotherapy.** *Cancer* 1989;63(6 Suppl):995-1007.
6. Borrie, P. **Megaloblastic anemia during methotrexate treatment of psoriasis.** 1966. *Br. Med. J.* 1:1339.
7. Brohée D. **5-fluorouracil (5FU) with or without folinic acid (LV) in human colorectal cancer? Multivariate meta-analysis of the literature.** *Med. Oncol. & Tumor Pharmacother* 1991; 8(4):271-80.
8. Carmichael J, Popiela T, Radstone D, et al. **Randomized comparative study of tegafur/uracil and oral leucovorin versus parenteral fluorouracil and leucovorin in patients with previously untreated metastatic colorectal cancer.** *J Clin Oncol* 2002;20(17):3617-27.
9. Chanarin I, Laidlaw J, Loughridge LW, et al. **Megaloblastic anemia due to phenobarbitone; the convulsant action of therapeutic doses of folic acid.** *Br Med J* 1960;1(5179):1099-102.
10. Clinical overview of Leucovorin: Addition of Adverse Drug Reaction Frequencies and Categories to the Leucovorin (Calcium Folate) Core Data Sheet. Pfizer. May 2016.
11. DeLap R.J. **The effect of leucovorin on the therapeutic index of fluorouracil in cancer patients.** *The Yale Journal of Biology and Medicine* 1988; 61:23-34.

12. DeVita V.T. Jr., Hellman S., Rosenberg S.A. Cancer, Principles & Practice of Oncology, 3rd Ed., pp. 355-359.
13. DeVita V.T. Jr., Hellman S., Rosenberg S.A. Cancer, Principles & Practice of Oncology, 4th Ed., pp. 964-965.
14. Doroshow J.H., Bertrand M., Newman E., Multhauf P., Leong L., Blayney D., Goldberg D., Margolin K., Carr B., Akman S. Metter G. **Preliminary analysis of a randomized comparison of 5-fluorouracil versus 5-fluorouracil and high-dose continuous-infusion folinic acid in disseminated colorectal cancer.** NCI Monogr 1987; 5:171-74.
15. Doroshow J.M., Multhauf P., Leong L., Margolin K., Litchfield T., Adman S., Carr B., Bertrand M., Goldberg D., Blayney D., Odujinrin O., DeLap R., Shuster J., Newman E. **Prospective randomized comparison of Fluorouracil and Fluorouracil and high-dose continuous infusion Leucovorin Calcium for the treatment of advanced measurable colorectal cancer in patients previously unexposed to chemotherapy.** J Clin Oncol 1990; 8:491-501.
16. Douillard JY, Hoff PM, Skillings JR, et al. **Multicenter phase III study of uracil/tegafur and oral leucovorin versus fluorouracil and leucovorin in patients with previously untreated metastatic colorectal cancer.** J Clin Oncol 2002;20(17):3605-16.
17. Erlichman C. **Fluorouracil and Leucovorin for metastatic colorectal cancer.** J of Chemotherapy 1990; 2(1):38-40).
18. Erlichman, C., Fine S., Wong A., Elhakim T. **A randomized trial of fluorouracil and folinic acid in patients with metastatic colorectal carcinoma.** J Clin Oncol 1988; 6:469-75
19. Frei, E., Blum, R.H. et al. **High dose methotrexate with leucovorin rescue, rationale and spectrum of antitumor activity.** 1980. Am. J. Med. 68:370.
20. Fluorouracil Injection [Prescribing information]. Spectrum Pharmaceuticals, Inc; 2016.
21. Goldie, J.H., Price, L.A. and Harrap, K.R. **Methotrexate toxicity: correlation with duration of administration, plasma levels, dose and excretion pattern.** 1972. Eur. J. Cancer 8:409.
22. Humblet Y. **Expert report on the toxicological and pharmacological documentation. Leucovorin Calcium Injection.** BC & A Quality Assurance in Clinical Research 1994.

23. Izak, G. **The effect of small doses of folic acid in nutritional megaloblastic anemia.** 1973. Amer. J. Clin. Nutr. 13:369.
24. Jardine LF, Ingram LC, Bleyer WA. **Intrathecal leucovorin after intrathecal methotrexate overdose.** J Pediatr Hematol Oncol 1996;18(3):302-4.
25. Keyomarsi, K. and Moran, R.G. **Mechanism of the cytotoxic synergism of fluoropyrimidines and folinic acid in mouse leukemic cells.** 1988. J. Biol. Chem. 263(28):14402.
26. Kido Y, Okamura T, Tomikawa M, et al. **Hypocalcemia associated with 5-fluorouracil and low dose leucovorin in patients with advanced colorectal or gastric carcinomas.** Cancer 1996;78(8):1794-7.
27. Leichman C.G., Leichman L., Spears C.P., Rosen P.J., Jeffers S., Groshen S. **Prolonged continuous infusion of Fluorouracil with weekly bolus Leucovorin: A Phase II Study in patients with disseminated colorectal cancer.** J Natl Cancer Inst 1993; 85:41-44
28. Levitt, M., Mosher, M.B. et al. **Improved therapeutic index of methotrexate with 'leucovorin rescue'.** 1973. Cancer. Res. 33:1729.
29. Lieberman, F.L. **Megaloblastic anemia possibly induced by trimetereine in patients with alcoholic cirrhosis.** 1968. Ann. Intern. Med. 68(1):168.
30. Machover D., Goldschmidt E., Schwarzenberg L., Vanden-Bulcke J.M., Misset J.L., Chollet P., Mathé G. **Treatment of advanced colorectal and gastric adenocarcinomas with 5-Fluorouracil combined with high-dose folinic acid. An update.** Chemioterapia. 1985; IV:369-76
31. Mane, J. et al. **Congenital folate-dependent megaloblastic anaemia of unknown aetiology.** 1977. Lancet January:262.
32. Mehta, B.M., Gisolfi, A.I. et al. **Serum distribution of citrovorum factor and 5-methyltetrahydrofolate following oral and i.m. administration of calcium leucovorin in normal adults.** 1978. Cancer Treat. Rep. 62(3):345.
33. Meropol NJ, Creaven PJ, Petrelli NJ, et al. **Seizures associated with leucovorin administration in cancer patients.** J Natl Cancer Inst 1995;87(1):56-8.

34. Mitchell DC, Vilter RW, Vilter CF. **Hypersensitivity to folic acid.** *Ann Intern Med* 1949; 31(6):1102-5.
35. Nixon, P.F. **Folinic acid: Pharmacokinetics and pharmacodynamics.** 1979. *Clin. Exp. Pharmacol. Physiol.* 5:35.
36. Nixon, P.F. and Bertino, J.R. **Effective absorption and utilization of oral formyltetrahydrofolate in man.** 1972. *N. Engl. J. Med.* 286(4):175.
37. Nobile M.T., Rosso R., Sertoli M.R., Rubagotti A., Vidili M.G., Guglielmi A., Venturini M., Canobbio L., Fassio T., Gallo L., Galligioni E., Gallotti P., Bruzzi P., Sobrero A. **Randomised comparison of weekly bolus 5-Fluorouracil with or without Leucovorin in metastatic colorectal carcinoma.** *Eur J Cancer* 1992; 28A(11):1823-27.
38. Nunn, P.P. and Allistone, J.C. **Resistance to trimethoprim-sulfamethoxazole in the treatment of Pneumocystis carinii pneumonia. Implications of folinic acid.** 1984. *Chest* 86(1):149.
39. O'Connell M.J., Klaassen D.J., Everson L.K., Cullinan S., Wieand H.S. **Clinical studies of biochemical modulation of 5-fluorouracil by leucovorin in patients with advanced colorectal cancer by the North Central Cancer Treatment Group and Mayo Clinic.** *NCI Monogr* 1987; 5:185-88.
40. Palmieri G., Gridelli C. Airoma G., Balestrino M., Bisogno A., Incoronato P., Bianco A.R. **Clinical trial with 5-Fluorouracil and Leucovorin.** *J of Chemotherapy* 1990; 2(1):41-6)
41. Piedbois P., Buyse M., Rustum Y., Machover D., Erlichman E., Carlson R.W., Valone F., Labianca R., Doroshow J.H., Petrelli N. **Modulation of fluorouracil by leucovorin in patients with advanced colorectal cancer: Evidence in terms of response rate.** *J Clin Oncol* 1992; 10(6):896-903
42. Prabu R, Bakhshi S. **Systemic reaction to leucovorin in a child with lymphoblastic lymphoma suggestive of hypersensitivity.** *Pediatr Blood Cancer* 2009;52(1):148.
43. Reynolds EH. **Effects of folic acid on the mental state and fit-frequency of drug-treated epileptic patients.** *Lancet* 1967;1(7499):1086-8.
44. Roman, J. et al. **The occurrence of megaloblastic anemia with normal serum folate during antipurine therapy.** 1973. *Clin. Res.* 21(1):94.

45. Safrin S, Lee BL, Sande MA. **Adjunctive folinic acid with trimethoprim-sulfamethoxazole for *Pneumocystis carinii* pneumonia in AIDS patients is associated with an increased risk of therapeutic failure and death.** *J Infect Dis* 1994;170(4):912-7.
46. Salim A, Tan E, Ilchyshyn A, et al. **Folic acid supplementation during treatment of psoriasis with methotrexate: a randomized, double-blind, placebo-controlled trial.** *Br J Dermatol* 2006;154(6):1169-74.
47. Schöber Ch., Bokemeyer C., Stahl M., Wilke H.J., Schmoll H-J., Poliwoda H. **The role of schedule dependency of 5-fluorouracil/leucovorin combinations in advanced colorectal cancer.** *Seminars in Oncology* 1992; 19(2):131-35.
48. Scott, J.M. **Folinic acid in megaloblastic anaemia of pregnancy.** 1957. *Br. Med. J.* August:270.
49. Sesin GP, Kirschenbaum H. **Folic acid hypersensitivity and fever: a case report.** *Am J Hosp Pharm* 1979;36(11):1565-7.
50. Steinke B., Günther E., Hirschmann W-D., Sondern W., Koniczek K-H., Wander H-E., Natt F., Wagner T., Hinrichs H-F., Werdier D. **Fluorouracil versus folinic acid/fluorouracil in advanced colorectal cancer - Preliminary results of a randomized trial.** *Seminars in Oncology* 1992;19(3):141-47
51. Su, P.C. **Congenital folate deficiency.** 1976. *N. Eng. J. Med.* May:1128.
52. Tong, M.J., Strickland, G.T. et al. **Supplemental folates in the therapy of Plasmodium falciparum malaria.** 1970. *JAMA* 214(13:233).
53. Trissel LA, Martinez JF, Xu QA. **Incompatibility of fluorouracil with leucovorin calcium or levoleucovorin calcium.** *Am J Health Syst Pharm* 1995;52(7):710-5.
54. Veldhorst-Janssen NM, Boersma HH, de Krom MC, et al. **Oral tegafur/folinic acid chemotherapy decreases phenytoin efficacy.** *Br J Cancer* 2004 9;90(3):745.
55. Whitehead, V.M., Pratt, R. et al. **Intestinal conversion of folinic acid to 5-methyltetrahydrofolate in man.** 1972. *Brit. J. Haematol.* 22:63.
56. Whitehead, V.M. et al. **Response to folinic acid in B₁₂ deficiency.** 1971. *Lancet* September:552.

57. Yoshimatsu K, Yokomizo H, Fujimoto T, et al. **First-line chemotherapy with low-dose leucovorin plus 5-flourouracil (LV/5-FU) for elderly patients with metastatic colorectal cancer.** *Anticancer Res* 2007;27(3B):1641-4.
58. Zhao R, Diop-Bove N, Visentin M, et al. **Mechanisms of membrane transport of folates into cells and across epithelia.** *Annu Rev Nutr* 2011;31:177-201.

Date of Revision: L3: 03 June 2020 (June 21, 2018)

Pfizer Canada ULC
Kirkland, Québec H9J 2M5